IO Biotech

IO Biotech is a clinical-stage biopharmaceutical company developing novel immune-modulating cancer therapies based on its T-win® technology platform. The T-win® platform is a new cancer immunotherapy approach designed to activate naturally occurring T cells to target immunosuppressive mechanisms. IO Biotech is advancing the clinical investigation of its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, while progressing the clinical and preclinical development of its other pipeline candidates.